Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

58.10 -1.72 (-2.88%)

Streaming Delayed Price Updated: 9:44 AM EDT, Mar 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

July 28, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗

July 25, 2025

Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.

Via Investor's Business Daily

Topics Death

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 24, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗

July 23, 2025

Via Stocktwits

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

August 01, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? ↗

July 29, 2025

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,...

Via Benzinga

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗

July 28, 2025

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.

Via Benzinga

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗

July 23, 2025

Via Benzinga

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

July 23, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review ↗

July 22, 2025

Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.

Via Benzinga

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

July 21, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

July 08, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

June 23, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' ↗

June 04, 2025

Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round."

Via Benzinga

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

June 02, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 29, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Archer Aviation Posts Narrower-Than-Expected Loss, Joins Microvast, Intuitive Machines And Other Big Stocks Moving Higher On Tuesday ↗

May 13, 2025

Via Benzinga

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

May 13, 2025

Via Benzinga

Which stocks are moving after the closing bell on Monday? ↗

May 12, 2025

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 12, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Insights Ahead: Arrowhead Pharma's Quarterly Earnings ↗

May 09, 2025

Via Benzinga

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 07, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

April 30, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

April 15, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 04, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases ↗

March 10, 2025

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.

Via Benzinga

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

March 10, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.